The economic environment for biotech and pharma drug developers today is challenging, marked by tightening financial pressures and rapidly evolving regulatory landscapes that are redefining development strategies.
Biotech IPO activity has plummeted over 75% from its 2021 peak, with only 20 global offerings completed in
2024 compared to 104 three years earliert. The Nasdaq XBI index declined by over 60% from its February 2021 peak, signaling broad valuation compression and investor risk aversion 2. Many early and mid-stage companies are resorting to bridge or extension financings at flat or reduced valuations to extend their runways.
Click here to read the full article
Our unique approach can help your company navigate the complexities of launching a drug, biologic or medical device into multiple markets. The first step? Connecting. Simply fill out our form and a representative will follow-up shortly.
1.877.787.0177
510.732.0177
Pharmatech Associates, Inc. 9110 Alcosta Blvd. STE H #601 San Ramon CA 94583
